康威

Conway Biotech is a clinical-stage biopharmaceutical company based in Guangzhou, China, dedicated to developing novel small molecule immunotherapies for cancer and autoimmune diseases. The company's core expertise lies in the activation of the innate immune system, specifically targeting Toll-like receptors (TLR) and the STING pathway. Their lead clinical asset, CWA214, is a dual TLR7/8 agonist designed to transform the tumor microenvironment and enhance anti-tumor immune responses. Led by a team of industry veterans with global drug development experience, Conway Biotech is advancing a robust pipeline of candidates through internal R&D and strategic partnerships. The company focuses on addressing cold tumors that are typically resistant to current checkpoint inhibitor therapies. With significant backing from prominent venture capital firms, Conway Biotech aims to provide innovative and affordable treatment options for patients globally.